Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors purchased 143,752 call options on the company. This represents an increase of ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

It wasn't all positive for Pfizer and BioNTech on the patent front this week, though. In Germany, the Düsseldorf Regional Court ruled for Moderna in a case that also dates back to 2022. The court ...

Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN). Moderna (NasdaqGS:MRNA) recently faced significant legal challenges with five international lawsuits from ...

March 5, 2025 Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the ...